LI Hu , HAN Yue , RU Xiangxiang , LI Xinxi , ZHANG Lei , DI Tao , Zaiying Yelbao , TIAN Ye
  • Digestive Vascular Center, Department of Vascular and Thyroid Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, P. R. China;
TIAN Ye, Email: chinese1018@126.com
type 2 diabetes mellitus; lower extremity atherosclerosis obliterans; free triiodothyronine; risk factors; nomogram prediction model
10.7507/1007-9424.202405074
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To explore the risk factors affecting occurrence of arteriosclerosis obliterans (ASO) for patients with type 2 diabetes mellitus (T2DM) and to develop a nomogram predictive model for these risk factors. Methods A case-control study was conducted. The patients with T2DM accompanied with ASO and those with T2DM alone, admitted to the First Affiliated Hospital of Xinjiang Medical University from January 2017 to December 2022, were retrospectively collected according to the inclusion and exclusion criteria. The basic characteristics and relevant laboratory test indicators of two groups were compared. The multivariate logistic regression analysis was used to identify the risk factors for the occurrence of ASO in the patients with T2DM, and then a nomogram predictive model was developed. Results The study included 119 patients with T2DM alone and 114 patients with T2DM accompanied with lower extremity ASO. The significant differences were observed between the two groups in terms of smoking history, white blood cell count, neutrophil count, lymphocyte count, platelet count, systemic immune-inflammation index, systemic inflammatory response index (SIRI), high-density lipoprotein cholesterol, apolipoprotein A1 (ApoA1), apolipoprotein α (Apoα), serum cystatin C, free-triiodothyronine (FT3), total triiodothyronine, free triiodothyronine / total triiodothyronine ratio, fibrinogen (Fib), fibrinogen degradation products, and plasma D-dimer (P<0.05). Further the results of the multivariate logistic regression analysis revealed that the history of smoking, increased levels of Fib and SIRI value increased the probability of occurrence of ASO in the patients with T2DM [OR (95%CI) = 2.921 (1.023, 4.227), P=0.003; OR (95%CI) =2.641 (1.810, 4.327), P<0.001; OR (95%CI) = 1.020 (1.004, 1.044), P=0.018], whereas higher levels of ApoA1 and FT3 were associated with a reduced probability of occurrence of ASO in the patients with T2DM [OR (95%CI) = 0.231 (0.054, 0.782), P=0.018; OR (95% CI) = 0.503 (0.352, 0.809), P=0.003]. The nomogram predictive model based on these factors demonstrated a good discrimination for predicting the ASO in the T2DM patients [area under the receiver operating characteristic curve (95%CI) =0.788 (0.730, 0.846)]. The predicted curve closely matched the ideal curve (Hosmer-Lemeshow goodness-of-fit test, χ2= 5.952, P= 0.653). The decision curve analysis showed that the clinical net benefit of intervention based on the nomogram model was higher within a threshold probability range of 0.18 to 0.80 compared to no intervention or universal intervention. Conclusion The analysis indicates that T2DM patients with a smoking history, elevated Fib level, and reduced levels of ApoA1 and FT3 should be closely monitored for ASO risk. The nomogram predictive model based on these features has a good discriminatory power for predicting ASO in T2DM patients, though its value warrants further investigation.